Brandtree

Sarepta: brands it owns and its ownership tree

Sarepta (NASDAQ: SRPT) is a publicly listed company headquartered in Cambridge, United States that owns 4 consumer brands.[1]

Sarepta is a US company that develops treatments for Duchenne muscular dystrophy. Its 2025 Form 10-K reports sales of Elevidys and three exon-skipping medicines.

Company facts

Legal name
Sarepta Therapeutics, Inc.
Headquarters
🇺🇸 Cambridge, United States
Type
publicly listed company · all publicly listed company owners
Tickers
NASDAQ: SRPT
Identifiers
SEC CIK 0000873303
Last verified
· 1 sources

Brands Sarepta owns

4 brands in 1 category.

Drug makers (4)

  • Amondys 45

    Biotechnology · 🇺🇸 United States

  • Elevidys

    Biotechnology · 🇺🇸 United States

  • Exondys 51

    Biotechnology · 🇺🇸 United States

  • Vyondys 53

    Biotechnology · 🇺🇸 United States

Full list of 4 brands with sources · Interactive ownership tree

Ownership structure

No company is recorded as controlling Sarepta.

Who owns the shares of Sarepta

Holders of more than 5% of the voting shares, as listed in Sarepta's proxy statement filed 24 April 2026. Shareholdings change daily; this is the position the filing reports.

HolderSharesShare of class
BlackRock, Inc.13,232,65212.5%
Entities Affiliated with AQR Capital Management8,104,8697.7%
State Street Corporation5,304,9075%

Financials and filings

Sarepta financial history

Headline figures from Sarepta's annual reports filed with the US Securities and Exchange Commission, in USD as reported, fiscal years ending 2020–2025. Revenue moved from $455.9m to $1.86bn, an average of 32.5% a year (calculated).

Fiscal year endedRevenueOperating incomeOperating marginNet incomeTotal assetsLong-term debtFiling
$1.86bn $-699,781,000 -37.5% $-713,410,000 $3.35bn — 10-K
$1.79bn $218.1m 12.2% $235.2m $3.96bn — 10-K
$1.14bn $-267,824,000 -23.4% $-535,977,000 $3.26bn — 10-K
$843.8m $-536,201,000 -63.5% $-703,488,000 $3.13bn — 10-K
$612.4m $-459,710,000 -75.1% $-418,780,000 $3.15bn — 10-K
$455.9m $-564,163,000 -123.8% $-554,128,000 $2.98bn — 10-K

Source: SEC XBRL company facts. A dash means the company did not report that line in a form we could read. Figures for a year can be restated in a later filing; the latest filing's number is shown.

Sarepta SEC filings

The documents behind the figures on this page, as listed in the SEC's EDGAR index. Each links to the filing itself.

Annual reports

Proxy statements

Recent current and quarterly reports

FiledFormWhat it declares
8-KResults of operations and financial condition
10-QQuarterly report
8-KEntry into a material agreement
8-KResults of operations and financial condition
10-QQuarterly report
8-KDeparture or appointment of directors or officers; Regulation FD disclosure
8-KDeparture or appointment of directors or officers; Results of a shareholder vote
8-KResults of operations and financial condition
10-QQuarterly report
8-KDeparture or appointment of directors or officers
8-KResults of operations and financial condition
8-KResults of operations and financial condition
8-KEntry into a material agreement; Creation of a direct financial obligation
8-KUnregistered sales of equity securities; Other events

Sarepta in the global legal-entity registry

The Global Legal Entity Identifier Foundation (GLEIF) keeps an open register of legal entities. Each entity reports its own parents. We show it as a cross-check on the ownership recorded on this page, which is built from filings.

Legal entity identifier (LEI)
549300IKDPIED8J8IG21
Registered name
SAREPTA THERAPEUTICS, INC. (US)
Registration status
Issued · record updated 5 August 2026
Parent
None named: it reports that it has no parent that consolidates its accounts.
Retrieved
· GLEIF record (JSON)

Frequently asked questions

What brands does Sarepta own?

Sarepta owns 4 consumer brands tracked here, including Amondys 45, Exondys 51, Vyondys 53 and Elevidys.

Is Sarepta an American company?

Yes. Sarepta is headquartered in Cambridge, United States.

Who owns Sarepta?

Sarepta is a publicly listed company owned by its shareholders; it trades as SRPT on the NASDAQ.

Sources (1) & corrections

Last verified . Every ownership fact above is backed by one of these primary documents. Numbers in brackets in the text refer to this list.

  1. [1] Sarepta Therapeutics, Inc. Annual Report on Form 10-K filed 2026-03-02 — SEC EDGAR, SEC Form 10-K, published 2 March 2026; retrieved 8 November 2026.

Report a correction Opens a pre-filled GitHub issue. See our corrections policy.